Amarex Founder and CEO, Dr. Kazem Kazempour, Appointed to George Washington University's Regulatory Affairs Advisory Board
Germantown, MD, USA (December 04, 2013) – As an expert drug and device regulatory leader, Amarex's CEO Dr. Kazem Kazempour has been appointed to the Advisory Board for George Washington University's newly established Regulatory Affairs program.
Dr. Kazempour will use his 15 years at the helm of Amarex and his 20+years as a biostatistician for the FDA and various pharmaceutical companies to provide a combined perspective from industry and FDA, to help create networks for students and graduates of the program, and to ensure the program's curriculum incorporates skills that meet today's business needs. Dr. Kazempour stated: "It is an honor and a privilege to be appointed to George Washington University's Regulatory Affairs Advisory Board , and I hope to serve as a guide for the program's mission in educating the next generation of international regulatory leaders."
GW's School of Medicine and Health Sciences recently established the Regulatory Affairs Program to prepare graduates to meet the challenges of dealing with FDA regulated products.
Dr. Daniela Drago, the Program's Director, stated that "[the Advisory Board is a] group of accomplished professionals with diverse backgrounds. They will provide key contributions to our strategic direction. Their input and expertise will enable us to keep our finger on the pulse of the industry."
Visit the Advisory Board webpage at https://smhs.gwu.edu/regulatory-affairs/board.
About Amarex Clinical Research
Amarex is a global, full service Contract Research Organization (CRO), whose leadership team has significant expertise conducting biomedical research, and whose combined experience includes the design and conduct of several hundred clinical research projects in many therapeutic indications. Amarex provides comprehensive services in Project Management (Phase I-IV, BE/BA, PK/PD), Regulatory Affairs, FDA Applications and Submissions, Applications and Submissions to international Health Authorities, GxP Compliance Audits, Clinical Operations, Adaptive Study Designs, Statistical Analysis, Data Management and General Consulting. Amarex has taken clients’ products through the entire approval process from writing the initial product approval strategy to the marketing approval application with a growing list of approved products. Amarex is committed to cost effective, high quality clinical product development.
Book a meeting or send us a message to talk to one of our experts.